Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Ayme

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Why are local recurrences after breast-conserving therapy more frequent in younger patients?J M Kurtz, J Jacquemier, R Amalric, et al.
Progress in Clinical and Biological Research|January 1, 1982
Does infrared thermography truly have a role in present-day breast cancer management?R Amalric, D Giraud, C Altschuler, et al.
Helvetica Chirurgica Acta|January 1, 1978
[Curative conservative treatment of benign operable breast cancers (705 cases with a 5-year follow-up)]J M Spitalier, H Brandone, Y Ayme, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1990
The prognostic significance of late local recurrence after breast-conserving therapyJ M Kurtz, J M Spitalier, R Amalric, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Is breast conservation after local recurrence feasible?J M Kurtz, J Jacquemier, R Amalric, et al.
Annals of Surgery|July 1, 1990
Breast-conserving therapy for macroscopically multiple cancersJ M Kurtz, J Jacquemier, R Amalric, et al.
Cancer|April 15, 1990
Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapyJ M Kurtz, J Jacquemier, R Amalric, et al.
Bulletin Du Cancer|April 1, 1976
[Curative radiotherapy with hope of saving the breast in operable breast cancers 403 cases with 5-year survival]R Amalric, R Clément, F Santamaria, et al.
Marseille Medical|January 1, 1970
[Our 1st 50 cases of discontinued associated chemotherapy palliative in late cancers (results of more than 9 months)]H Brandone, Y Ayme, J Levraud, et al.
Breast Cancer Research and Treatment|January 1, 1993
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifenE Garcia-Giralt, Y Ayme, M Carton, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Why are local recurrences after breast-conserving therapy more frequent in younger patients?J M Kurtz, J Jacquemier, R Amalric, et al.
Progress in Clinical and Biological Research|January 1, 1982
Does infrared thermography truly have a role in present-day breast cancer management?R Amalric, D Giraud, C Altschuler, et al.
Helvetica Chirurgica Acta|January 1, 1978
[Curative conservative treatment of benign operable breast cancers (705 cases with a 5-year follow-up)]J M Spitalier, H Brandone, Y Ayme, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1990
The prognostic significance of late local recurrence after breast-conserving therapyJ M Kurtz, J M Spitalier, R Amalric, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Is breast conservation after local recurrence feasible?J M Kurtz, J Jacquemier, R Amalric, et al.
Annals of Surgery|July 1, 1990
Breast-conserving therapy for macroscopically multiple cancersJ M Kurtz, J Jacquemier, R Amalric, et al.
Cancer|April 15, 1990
Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapyJ M Kurtz, J Jacquemier, R Amalric, et al.
Bulletin Du Cancer|April 1, 1976
[Curative radiotherapy with hope of saving the breast in operable breast cancers 403 cases with 5-year survival]R Amalric, R Clément, F Santamaria, et al.
Marseille Medical|January 1, 1970
[Our 1st 50 cases of discontinued associated chemotherapy palliative in late cancers (results of more than 9 months)]H Brandone, Y Ayme, J Levraud, et al.
Breast Cancer Research and Treatment|January 1, 1993
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifenE Garcia-Giralt, Y Ayme, M Carton, et al.
Pageof 5